Quick Summary: TMS may be worth considering when depression has not improved with antidepressants, medication side effects are difficult to manage, or a patient wants to discuss non-medication treatment options with a qualified clinician. In New Jersey, Dr. Matthew Zuch, co-founder of NeuroBoost, is helping expand awareness of TMS for adults with treatment-resistant depression, OCD, anxiety, and related mental health concerns.
A person should consider Transcranial Magnetic Stimulation (TMS) when depression remains persistent despite appropriate treatment, medications have produced difficult side effects, or a non-medication approach is worth discussing with a qualified mental health professional. TMS is a non-invasive form of brain stimulation that has become an established option for adults with treatment-resistant depression, while research and FDA clearances have also expanded its use in conditions including obsessive-compulsive disorder (OCD), depression with anxiety, and smoking dependence.
For patients and families in Northern New Jersey, understanding where TMS fits into the broader landscape of mental health care can be particularly important. Dr. Matthew Zuch, co-founder of NeuroBoost, is a New Jersey clinical psychologist whose work includes helping patients understand evidence-based approaches to depression, anxiety, OCD, and related behavioral health concerns. Dr. Matthew Zuch’s clinical background is outlined on his professional website, while NeuroBoost provides TMS-focused care in Bloomfield, New Jersey.
Depression does not affect every patient in the same way, and treatment often requires adjustment over time. Antidepressants remain an important treatment for many people, but they can take several weeks to work and may produce side effects that make continued treatment difficult. The National Institute of Mental Health notes that treatment-resistant depression is generally considered when symptoms do not improve after attempts with at least two antidepressants.
That distinction matters. A person does not necessarily need to exhaust every available treatment before discussing TMS, but persistent symptoms, inadequate response, medication intolerance, or a preference for a non-medication treatment for depression can all justify a clinical conversation.
TMS is particularly relevant because it approaches depression differently from medication. During TMS treatment, an electromagnetic device delivers repeated magnetic pulses to targeted areas of the brain. The procedure is non-invasive and does not require general anesthesia. NIMH describes repetitive TMS as an established brain-stimulation treatment for depression and notes that evidence supports its ability to reduce depressive symptoms in people for whom medication has been ineffective or intolerable.
Research continues to refine understanding of who responds best to TMS and which protocols are most effective. A 2024 systematic review and meta-analysis of five randomized controlled trials involving 507 people with treatment-resistant depression found that deep TMS produced higher response and remission rates than control treatment. The reported response rate was 45.3% compared with 24.2% in controls, while remission occurred in 38.3% compared with 14.4%.
These figures do not mean TMS works for everyone, and they should not be interpreted as a guarantee of an individual outcome. They do, however, help explain why TMS has become an important part of the conversation around treatment-resistant mental health disorders.
TMS has also moved beyond depression. The FDA permitted marketing of a TMS system for OCD in 2018, and NIMH currently lists rTMS among cleared treatments for treatment-resistant depression, OCD, anxiety with depression, and smoking dependence. Research into treatment-resistant OCD has continued, including a 2024 meta-analysis of randomized trials that found greater response with active deep TMS than sham treatment.
The evidence for treatment-resistant anxiety itself is less settled. A recent systematic review found promising symptom improvements but emphasized limitations in the existing research, including small studies and limited long-term follow-up. That distinction is important for patients considering TMS as an anxiety treatment option: clinical evaluation should determine whether the treatment is appropriate rather than assuming that every form of anxiety is an established TMS indication.
The practical question, then, is less “Have I tried everything?” and more “Has my current treatment plan produced enough improvement, and are there other evidence-based options worth considering?”
A consultation can review diagnosis, previous treatments, medication response, medical history, and treatment goals. A psychiatrist referral for TMS may be appropriate depending on a person’s care team and circumstances. For adults considering TMS, the evaluation process should establish whether the clinical indication, treatment history, and individual circumstances support moving forward.
That approach is central to responsible mental health innovation. At NeuroBoost in Bloomfield, New Jersey, Dr. Matthew Zuch’s work connects TMS therapy with individualized evaluation for adults exploring treatment-resistant depression care and non-medication treatment options. TMS should be viewed as one component of a broader range of depression treatment options and OCD treatment options, alongside psychotherapy, medication, and other established interventions.
For people in Montclair, Bloomfield, Essex County, and communities throughout Northern New Jersey, access to specialized care can make that conversation more practical. NeuroBoost’s Bloomfield location focuses on TMS treatment, while Dr. Zuch’s broader clinical work addresses anxiety, depression, OCD, and related concerns. TMS therapy in New Jersey can therefore represent an avenue for adults exploring alternatives to antidepressants or seeking a non-invasive depression treatment after conventional approaches have fallen short.
TMS for smoking cessation represents another developing area of brain-stimulation care; the FDA has cleared a TMS device as an aid for short-term smoking cessation in adults.
Ultimately, the decision to consider TMS belongs within an individualized clinical assessment. For someone still struggling with treatment-resistant depression, treatment-resistant OCD, or other persistent symptoms, asking about TMS may be a reasonable next step, not because it replaces existing mental health care, but because it expands the range of evidence-based options available to adults who need another path forward.
